https://www.sciencealert.com/alzheimers-might-not-actually-be-a-brain-disease-expert-reveals

Alzheimer's Might Not Actually Be a Brain Disease, Expert Reveals

The key information is "Whether this association represents a correlation, or a causality is still awaiting mechanistic studies."

Five studies linked to Cassava Sciences retracted
https://retractionwatch.com/2022/03/30/five-studies-linked-to-cassava-biosciences-retracted/

From option it looks like the SP will be ended up with <22.8 today.

It is amazing that the number of shares for SAVA traded today is half of its total shares!

Long-Awaited Alzheimer’s Disease Diagnostic May Be a Reality

They used IR spectrum on skin cells to diagnose ealy state Alz.

https://clpmag.com/diagnostic-technologies/molecular-diagnostics/amplification-technologies/long-awaited-alzheimers-disease-diagnostic-may-be-a-reality/?utm_campaign_type=newsletter&_hsmi=169193197&_hsenc=p2ANqtz-_sErGdZKAkBEKfpx72Kd3lx3AK5crJwLUBsyq_5SHGXRhQUAqLidxGdvH3WE9kihNuMaYMFZuDVvt4_6ajcJy2MPybOA

Bourbon, thanks for the updates. It is an excellent idea that AMGN could pay the front early. However, if we look at the mcp of adxs, which is 104m, AMGN could buy the whole adxs for say 400m now. am I missing something here?

Bourbon, thanks for the update. It is an excellent idea that AMGN pay more at front. However, I thought that the mcp of adxs is now only 103 m and AMGN can just buy it with the same amount of money (400m) if they want. Is something missing here?

Thanks,

What do you think about www.shortsqueeze.com?

Unfortunately the short interest increased 7% from 7.7 to 8.2 mil.

It is the amount of 150k to 200k.

A2-73 probably the only hope for Alzs.

Guys, this is probably an indicator how the passed tax bill would do to ADXS.

It is probably the reason.

Runcaly, it should be a good news for ADXS and that is why the SP changed in two days.

Penny, thanks for the info. Hope A-273 will participate in the consortium trial.

Gator, are you trying to set a higher target for A-273 in the case that it provided the best ever treatment for early stage of ALz patients? or something else?

Some one is desperate.

The cheapest Car-T is $30,0000 and so far does not work well with solid tumor.

Agree. People will try what ever possible since the real reason for AD is unknown yet.

Kite's new list price for the Car-T is $373,000. what the price for ADXS's drug?

The short interest on 10/1 is 4.1 m which reduced by 20% compared that in 9/15.

Perhaps this has been showed before, institutional ownership is 24.6%
10 hedge funds buy Anavex Life Sciences Corp. (AVXL) for the first time
https://postanalyst.com/2017/10/19/10-hedge-funds-buy-anavex-life-sciences-corp-avxl-for-the-first-time/

It shows that 1142k was traded on google.

Bourbon, I second you about the training one needs to do analysis for this type of bio companies.

Thought there is a rule that one needs to buy back the same stock after 30 days when sold it. It means that someone will buy back at the beginning of Nov.

The same thing happened yesterday for 147k.

I guess the shorts covered 1/3.

Someone just sold/bought 137k?

fbg, thanks for the info. It would be easy to confirm if it is true. Someone can check if he was working the same way when he sold the other company.

fbg, sorry I missed something here. What does the The Channel Group do?

which is the report from NSDQ on 9/15.

The current shorts are 9,936,700 (from shortsqueeze).

BarrellofHay, what I understand is the stock market is not a win-win game. The hedges can do what ever is legal. They always deprive money from retails.

The good news is that the shorts sense that a deal is imminent and they could not wait for covering any longer.

Is this the latest short number:10,028,400?

The slides for the presentation are now available.

fbg, my guess is that the shorts probably covered 1/3.

Another a 179k trade.

The HFT is the tool to manipulate the market. There is no equal access to the market as many of you know the black pool. If one got enough deep pocket one can do whatever one likes within the regulation.